AlexandriaPhanMD

PubMed

• 89 citations
  Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
  Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, Helen X. Chen
  British Journal of Cancer. 2013-03-05
• 91 citations
  Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study
  Alexandria T. Phan, Daniel M. Halperin, Jennifer A. Chan, David R. Fogelman, Kenneth R. Hess
  The Lancet. Oncology. 2015-06-01
• 196 citations
  The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (High-Grade) extrapulmonary neuroendocrine carcinomas
  Jonathan R. Strosberg, Domenico Coppola, David S. Klimstra, Alexandria T. Phan, Matthew H. Kulke
  Pancreas. 2010-08-01

Books/Book Chapters

• M D Anderson Cancer Center 100 years of History 
  Chapter: Gastric Cancer 
  Phan AT, Mansfield PEditors: Rodriguez A, Burke T.McGraw-Hill2013
• Neuroendocrine Tumors 
  Chapter: Adrenocortical carcinoma 
  Phan AT and Jimenez CEditors: Yao JC.Springer2011
• Oncologic Imaging 
  Chapter: Gastric Carcinoma 
  Vikram R, Patnana M, Devine K, Mansfield P, Phan ATEditors: Silverman PM.Elsevier2011
• Targeted Therapy in the Age of Personalized Cancer Care 
  Chapter: Targeted Therapy for Endocrine Neoplasms 
  Garg R, Agrawal M, Quintas-Cardama A, Phan ATEditors: Qintas-Cardaman A, Cataldo V, Gibbons D.Nova Science2011
• MD Anderson Manual of Clinical 
  Chapter: Carcinoma of the Esophagus and Gastric 
  Phan AT, Valero VEditors: Kantarjian H, Wolff RA, Koller C.McGraw-Hill2005
• Chemoradiation in Cancer Therapy 
  Chapter: Chapter 13-Combined Modality Therapy in Gastric, Pancreatic, and Biliary Tract Carcinomas 
  Phan AT, Ajani JAEditors: Hak Choy.Humana Press2003
• Join now to see all

Abstracts/Posters

• Risk of anxiety/depression events in patients newly diagnosed with neuroendocrine tumors
  C. Chen, G.P. Hess, Z. Liu, J.C. Yao, A.T. Phan, J.W. Hill, ASCO, 1/1/2011
• Risk of osteoporosis/osteopenia events in patients newly diagnosed with neuroendocrine tumors
  J.W. Hill, C. Chen, G.P. Hess, Z. Liu, J.C. Yao, A.T. Pha, ASCO, 1/1/2011
• Neuroendocrine tumor disease state and PROMIS health-related quality of life scores
  Cella D, Beaumont JL, Liu Z, Phan AT, Choi S, Yao JC, ASCO, 1/1/2010
• Relationship between neuroendocrine tumor-related symptoms and health-related quality of life
  Beaumont JL, Liu Z, Choi S, Yao JC, Phan AT, Cella D, ASCO GI, 1/1/2010
• Somatostatin analogue therapy and PROMIS health-related quality-of-life scores in patients with neuroendocrine tumors
  M. Dong, J.L. Beaumont, Z. Liu, A.T. Phan, S. Choi, D. Cella, J.C. Yao, ASCO, 1/1/2010
• A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC)
  Phan AT, Yao JC, Fogleman D, Hess KR, Ng CS, Bullock SA, Malinowski P, Regan E, Kulke M, ASCO, 1/1/2010
• Neuroendocrine tumor disease state and health-related quality of life
  Phan AT, Beaumont JL, Liu Z, Choi S, Cella D, Yao JC, ASCO GI, 1/1/2010
• Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G...
  Ko AH, Tabernero J, Garcia De Paredes M, Rivera F, Schnell FM, Baker JS. Phan AT, Alsina M, Patel K, Ajani JA, ASCO, 1/1/2010
• Association of neoadjuvant chemoradiation with improved survival in resectable gastric cancer
  Bose D., Badgwell B., Cormier J. N., Wen S, Yao J. C., Staerkel G. A., Crane C. H., Pisters P. W., Phan A., Mansfield P. F, GI ASCO, 1/1/2009
• A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin
  Sankhala K. K., Mita A. C., Adinin R., Wood L., Beeram M., Bullock S., Yamagata N., Matsuno K., Fujisawa T., Phan A, ASCO, 1/1/2009
• A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma
  Mani MA, Shroff RT, Jacobs C, Wolff RA, Ajani JA, Yao JC, Phan AT, ASCO, 1/1/2008
• The pharmacokinetics and pharmacodynamics of IMGN242 (huC242-DM4) in patients with CanAg-expressing solid tumors
  Qin A, Watermill J, Mastico RA, Lutz RJ, O’Keeffe J, Zildjian S, Mita AC, Phan AT, Tolcher AW, ASCO, 1/1/2008
• Phase I/II trial of docetaxel plus oxaliplatin and 5-fluorouracil (D-FOX) in patients with untreated, advanced gastric or gastroesophageal cancer
  Ajani JA, Phan AT, Ho L, Tetzlaff ED, Baker J, Wei Q, ASCO, 1/1/2007
• Phase II study of RAD001 and Depot Octreotide in patients with advanced low
  Phan AT, Chang DZ, Rashid A, Meric-Bernstam F, Yao JC, 8th World Congress on Gastrointestinal Cancer, 6/1/2006
• Phase I/II trial of capecitabine (C), dacarbazine (D) and imatinib (I) (CDI) for patients (pts) metastatic medullary thyroid carcinomas (MTC)
  Hoff PM, Hoff AO, Phan AT, Sherman SI, Yao JC, White N, Phan L, Abbruzzese JL, Gagel RF, ASCO, 1/1/2006
• Association of VEGF expression with poor prognosis among patients with low-grade neuroendocrine carcinoma
  Phan AT, Wang L, Xie K, Zhang J, Rashid A, Evans D, Vauthey J, Abdalla E, Abbruzzese JL, Yao JC, ASCO, 1/1/2006
• Join now to see all

Lectures

• Management of NET & Adrenal Cancers 
  1/1/2012
• Management of Advanced Gastric Cancer 
  1/1/2007
• Advances Management of Upper GI Cancers 
  1/1/2006
• Management of Adrenal Cancers 
  1/1/2004
• Join now to see all